You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. D peptide inhibitors of SIRPα anti phagocytic signaling

    SBC: NAVIGEN, INC.            Topic: 100

    PROJECT SUMMARY The cell surface CD protein is a marker of self and signals through its receptor signal regulatory protein SIRP expressed by macrophages to transmit an anti phagocytic donandapos t eat me signal CD is expressed by virtually all cell types is overexpressed by cancer cells as a mechanism to avoid immune surveillance and phagocytosis and is a negative prognostic f ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Evidence-Based Pain Intervention for Veterans: Leveraging Mobile and Social Media

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NCCIH

    Chronic musculoskeletal pain creates a significant public health burden, and Veterans are disproportionately affected. The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), all three conditions (Post-deployment Multi-symptom Disorder (PMD), and other multi-symptom syndromes can complicate and reduce the effectiveness of pain treatment. Furthermore, the ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Clinical Development of JS-K for the Treatment of Cancer

    SBC: JSK THERAPEUTICS INC.            Topic: 102

    PROJECT DESCRIPTIONJSK TherapeuticsJSKTDirect to Phase II Application Nitric oxideNOis a potentially powerful therapy against cancerSpontaneous NO generating drugs cannot be used to treat malignancies because of the pleiotropic effects of NOIn particularNO is a potent vasodilator with resultant hypotensionIn order to make NO based cancer therapy possibleit is necessary to develop agents that deliv ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. EEG Patch

    SBC: EPITEL, INC.            Topic: 105

    ABSTRACT The EEG PatchTM is a single channelelectrodewearablepatch like device designed for long termEEG recording in people with epilepsy to be used in their everyday environmentTo maximize the treatment of epilepsyit is critical to capture important day to day changes in EEG activity for long periods including the occurrence and duration of epileptiform events such The EEG Patch is unobtrusive a ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease

    SBC: EPIVAX, INC.            Topic: 200

    ABSTRACT SignificanceGravesdiseaseGDone of the most prevalent autoimmune diseasesis caused by stimulating autoantibodiesTSAbto the Thyroid Stimulating Hormone ReceptorTSHRresulting in hyperthyroidismCurrent methods for managing hyperthyroidism in GD target excess thyroid hormone secretion by ablation or removal of the thyroid or by blocking thyroid hormone synthesisEach of these therapies is assoc ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Topical Eyedrop Therapy for Keratoconus

    SBC: Iveena Delivery Systems, Inc.            Topic: N

    Project Summary Keratoconus KCN is a progressive disorder associated with structural changes in corneal collagen organization that leads to corneal thinning and ruptures in Bowman s layer and or Descemet s membrane As the disease progresses it leads to irregular astigmatism progressive myopia and subsequently poor visual acuity Treatment options are surprisingly limited with no oral or topi ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Novel iobio analysis supporting genome scale data quality control

    SBC: FRAMESHIFT LABS INC            Topic: 172

    Project Summary Identifying disease causing genetic variants is a complex process often involving the analysis of the genomes of affected patients and their immediate families When employing these state of the art techniques however the number of patients receiving a successful diagnosis is still only at approximately One reason for this low diagnosis rate is the presence of localised dat ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. POC for Quantifying Carbapenem produced KPC from Rectal Swabs in hours

    SBC: Guanine, Inc            Topic: NCZVBED

    Abstract Carbapenem resistant Enterobacteriaceae CRE pose a serious threat to public health These organisms cause infections that are associated with high mortality rates have the potential to spread widely and are resistant to all lactam agents and most other antimicrobials leaving virtually no treatment options Much CRE increase has been due to the spread of CRE that produce the carbapen ...

    SBIR Phase I 2017 Department of Health and Human ServicesCenters for Disease Control and Prevention
  9. Continuously Variable Displacement Engine Concept Validation

    SBC: Engine Systems Innovation, Inc.            Topic: 14d

    The gasoline engine is the prevalent engine in use today for automobiles and light trucks. In spite of the growth of various hybrids, clean diesel, and electric vehicles, it is projected to be in 71% of the vehicles produced globally in 2022. The gasoline engine has very poor efficiency at partial load typical of its usage in automobiles. Automobile engines can typically produce 200 or even 300 ho ...

    SBIR Phase II 2017 Department of Energy
  10. SBIR Phase I: Dual suppression of VEGF-A and PDGF-B with extended gene therapy for neovascular AMD

    SBC: Iveena Delivery Systems, Inc.            Topic: BM

    This SBIR Phase I project will determine the feasibility of a new high risk technology for treatment of age-related macular degeneration (AMD). The technology is an AAV2-mediated concurrent expression of recombinant proteins to intracellularly suppress the critical growth factors VEGF-A (vascular endothelial growth factor A) and PDGF-B (platelet-derived growth factor) in a single injection. AMD is ...

    SBIR Phase I 2017 National Science Foundation
US Flag An Official Website of the United States Government